{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T16:04:50Z","timestamp":1700582690184},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1016\/j.jacl.2009.02.003","type":"journal-article","created":{"date-parts":[[2009,2,18]],"date-time":"2009-02-18T01:42:50Z","timestamp":1234921370000},"page":"101-108","source":"Crossref","is-referenced-by-count":10,"title":["Flushing and other dermatologic adverse events associated with extended-release niacin therapy"],"prefix":"10.1016","volume":"3","author":[{"given":"John R.","family":"Guyton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillip D.","family":"Simmons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2009.02.003_bib1","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/0003-9861(55)90070-9","article-title":"Influence of nicotinic acid on serum cholesterol in man","volume":"54","author":"Altschul","year":"1955","journal-title":"Arch Biochem"},{"key":"10.1016\/j.jacl.2009.02.003_bib2","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1001\/archinte.160.8.1177","article-title":"Extended-release niacin versus gemfibrozil for treatment of low levels of high density lipoprotein cholesterol","volume":"160","author":"Guyton","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacl.2009.02.003_bib3","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1517\/14656566.5.6.1385","article-title":"Extended-release niacin for modifying the lipoprotein profile","volume":"5","author":"Guyton","year":"2004","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jacl.2009.02.003_bib4","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S0002-9149(03)00394-1","article-title":"Effects of extended-release niacin on lipoprotein subclass distribution","volume":"91","author":"Morgan","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2009.02.003_bib5","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11883-000-0096-y","article-title":"Niacin dosing: relationship to benefits and adverse effects","volume":"2","author":"Capuzzi","year":"2000","journal-title":"Curr Atheroscler Rep"},{"issue":"suppl.","key":"10.1016\/j.jacl.2009.02.003_bib6","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.amjcard.2006.11.018","article-title":"Safety considerations with niacin therapy","volume":"99","author":"Guyton","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2009.02.003_bib7","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0090-6980(89)90088-9","article-title":"Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid","volume":"38","author":"Morrow","year":"1989","journal-title":"Prostaglandins"},{"key":"10.1016\/j.jacl.2009.02.003_bib8","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0026-0495(98)90284-0","article-title":"Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia","volume":"47","author":"Knopp","year":"1998","journal-title":"Metabolism"},{"key":"10.1016\/j.jacl.2009.02.003_bib9","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/ajhp\/60.10.995","article-title":"Niacin for dyslipidemia: considerations in product selection","volume":"60","author":"McKenney","year":"2003","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jacl.2009.02.003_bib10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0002-9343(92)90018-7","article-title":"Hepatic toxicity of unmodified and time-release preparations of niacin","volume":"92","author":"Rader","year":"1992","journal-title":"Am J Med"},{"key":"10.1016\/j.jacl.2009.02.003_bib11","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1001\/jama.271.9.672","article-title":"A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients","volume":"271","author":"McKenney","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2009.02.003_bib12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/107424849600100302","article-title":"Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: a placebo-controlled trial","volume":"1","author":"Morgan","year":"1996","journal-title":"J Cardiovasc Pharmacol Therapeut"},{"key":"10.1016\/j.jacl.2009.02.003_bib13","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S0002-9149(00)00703-7","article-title":"Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia","volume":"85","author":"Goldberg","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2009.02.003_bib14","doi-asserted-by":"crossref","first-page":"74U","DOI":"10.1016\/S0002-9149(98)00731-0","article-title":"Efficacy and safety of an extended-release niacin (Niaspan); a long-term study","volume":"82","author":"Capuzzi","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2009.02.003_bib15","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1001\/archinte.162.14.1568","article-title":"Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes","volume":"162","author":"Grundy","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacl.2009.02.003_bib16","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0002-9149(98)00448-2","article-title":"Effectiveness of once nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia","volume":"82","author":"Guyton","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2009.02.003_bib17","series-title":"Niaspan product information. Physicians Desk Reference","author":"Kos Pharmaceuticals","year":"2005"},{"key":"10.1016\/j.jacl.2009.02.003_bib18","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/clc.4960260304","article-title":"A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin","volume":"26","author":"Hunninghake","year":"2003","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jacl.2009.02.003_bib19","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1001\/archinte.164.10.1121","article-title":"Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis","volume":"164","author":"Insull","year":"2004","journal-title":"Arch Intern Med"},{"issue":"suppl 12A","key":"10.1016\/j.jacl.2009.02.003_bib20","doi-asserted-by":"crossref","first-page":"35L","DOI":"10.1016\/S0002-9149(00)01468-5","article-title":"The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol","volume":"86","author":"Piepho","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2009.02.003_bib21","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/0026-0495(85)90092-7","article-title":"Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin","volume":"34","author":"Knopp","year":"1985","journal-title":"Metabolism"},{"key":"10.1016\/j.jacl.2009.02.003_bib22","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/clpt.1982.63","article-title":"Aspirin blocks nicotinic acid-induced flushing","volume":"31","author":"Wilkin","year":"1982","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacl.2009.02.003_bib23","doi-asserted-by":"crossref","first-page":"633","DOI":"10.5414\/CPP44633","article-title":"Improved control of niacin-induced flushing using an optimized once-daily, extended-release niacin formulation","volume":"44","author":"Cefali","year":"2006","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.jacl.2009.02.003_bib24","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.1073\/pnas.0601574103","article-title":"Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans","volume":"103","author":"Cheng","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacl.2009.02.003_bib25","unstructured":"Tredaptive (nicotinic acid\/laropiprant) authorised in the European Union: new lipid-modifying therapy to treat LDL-C, HDL-C and triglycerides. Available at: http:\/\/www.medicalnewstoday.com\/articles\/115760.php. Accessed August 28, 2008."},{"key":"10.1016\/j.jacl.2009.02.003_bib26","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.231.4.360","article-title":"The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease","volume":"231","year":"1975","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2009.02.003_bib27","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2009.02.003_bib28","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1161\/01.CIR.0000148955.19792.8D","article-title":"Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins","volume":"110","author":"Taylor","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2009.02.003_bib29","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1185\/030079906X148508","article-title":"The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3","volume":"22","author":"Taylor","year":"2006","journal-title":"Curr Med Res. Opin"},{"key":"10.1016\/j.jacl.2009.02.003_bib30","unstructured":"National Heart Lung and Blood Institute. Niacin plus statin to prevent vascular events, 2006. Available at: http:\/\/www.clinicaltrials.gov\/ct\/show\/NCT00120289. Accessed May 11, 2007."},{"key":"10.1016\/j.jacl.2009.02.003_bib31","unstructured":"University of Oxford. Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE, 2007. Available at: http:\/\/www.clinicaltrials.gov\/ct\/show\/NCT00461630. Accessed December 31, 2008."}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287409000786?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287409000786?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T23:30:35Z","timestamp":1633131035000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287409000786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["S1933287409000786"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2009.02.003","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2009,4]]}}}